|KOMISJA NADZORU FINANSOWEGO|
|Raport bieżący nr||2||/||2020|
|Skrócona nazwa emitenta|
|Receiving a Notice of Allowance on patent for CompuWave for integration into CompuFlo Epidural System|
|Art. 17 ust. 1 MAR - informacje poufne.|
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced that Milestone Scientific, Inc. (NYSE:MLSS), the majority shareholder of the Issuer has received a Notice of Allowance for a key patent from the U.S. Patent and Trademark Office on its CompuWave technology, which is being integrated into the CompuFlo® Epidural System.
The Notice of Allowance relates to an apparatus that combines both objective pressure measurements and the detection of a pulsatile pressure waveform in a single system. Utilizing a high-resolution in-line pressure sensor in combination with the unique data processing within the CompuFlo System makes it capable of detecting both the in-situ pressure as well as the presence of a pulsatile pressure waveform. The pulsatile waveform is representative of the detection of pressures that are produced by the cardio-vascular system either directly or indirectly. This in turn can be used to aid in the identification of a needle or a catheter within an anatomic structure such as the epidural space. This same system can be used to aid in the determination of the patency of a catheter and to assist in determining if a catheter has been displaced during a procedure.
The Board of Directors of the Issuer believes that this Notice of Allowance is an important advancement and line extension to Dynamic Pressure Sensing (DPS®) technology that is currently used in the CompuFlo Epidural System and the CompuWave technology represents a break-through for the CompuFlo Epidural System. This technology also has other medical applications, and the the Company plans to incorporate this innovative capability into future medical instruments for other indications as well.
The Issuer is constantly evolving and innovating the technology. This patent represents a significant achievement for the Company since it extends the IP protection around the CompuFlo instrument for another 20 years and provides not only additional confirmation of placement, but also verification during the procedure that the catheter has not been displaced. The Board of Directors of the Issuer believes that this advanced, patented technology further enhances the position of the Company at the forefront of the computerized injection market.
|MESSAGE (ENGLISH VERSION)|
|PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ|
|Data||Imię i Nazwisko||Stanowisko/Funkcja||Podpis|
|2020-01-16||Joseph D'Agostino||Chief Financial Officer||Josepg D'Agostino|